Topical estrogen, testosterone, and vaginal dilator in the prevention of vaginal stenosis after radiotherapy in women with cervical cancer: a randomized clinical trial

Table 4 Change in vaginal volume (%) in the different groups during follow-up (n = 142)

	N	Mean	SD	Min	Q1	Median	Q3	Max
Testosterone
0-4^a	31	−13.7	15.1	−43.1	−18.0	−10.6	0	10.7
4-8^b	29	−21.0	19.1	−60.8	−40.5	−13.2	−7.5	10.7
8-12^c	28	−24.6	18.3	−64.6	−41.8	−21.1	−8.8	10.7
Estrogen
0-4^a	53	−12.5	13.7	−51.4	−21.0	−9.6	0	10.6
4-8^b	46	−22.8	15.4	−57.1	−36.4	−18.4	−9.7	0
8-12^c	41	−26.3	16.1	−67.5	−37.0	−22.5	−13.8	0
Dilator
0-4^a	27	−8.4	14.65	−36.4	−21.4	−8.1	0	21.4
4-8^b	27	−15.1	21.3	−49.7	−30.0	−13.5	0	36.0
8-12^c	27	−23.9	23.8	−72.2	−39.2	−21.4	−5.7	12.0
Lubricant gel
0-4^a	60	−13.6	15.5	−68.5	−18.1	−9.7	0	9.7
4-8^b	48	−18.5	16.4	−57.8	−32.2	−13.4	−6.3	10.7
8-12^c	46	−26.2	18.4	−60.7	−45.1	−22.6	−10.7	10.7

ISSN: 1471-2407